Cellectis S.A.
CLLSNASDAQHealthcare● Active
$2.96
$-0.11(-3.43%)
Market Cap$296732566
P/E Ratio—
52W High$5.48
52W Low$1.327
Cellectis S.A. (CLLS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLLS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.18
Est. -$0.26 · +30.3%
Revenue
$0.01B
Est. $0.01B · -31.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
CLLS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.26 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.26 | -$0.18 | +30.3% | $0.01B | $0.01B | -31.6% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.20 | -$0.26 | -27.9% | $0.01B | $0.01B | -8.9% |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.10 | $0.01 | +110.0% | $0.04B | $0.01B | +242.4% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -$0.10 | -$0.24 | -140.0% | $0.02B | $0.01B | +106.0% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.19 | -$0.18 | +5.3% | $0.01B | $0.01B | -16.2% |
| ▼ Q1 FY2025 | Mar 13, 2025 | $0.06 | -$0.16 | -366.7% | $0.01B | $0.01B | +38.7% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -$0.20 | -$0.23 | -15.0% | $0.02B | $0.02B | -20.6% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.26
EPS Surpr.
+30.3%
Revenue
$0.01B
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.20
EPS Surpr.
-27.9%
Revenue
$0.01B
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.10
EPS Surpr.
+110.0%
Revenue
$0.04B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.10
EPS Surpr.
-140.0%
Revenue
$0.02B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.3%
Revenue
$0.01B
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.16
EPS Est.
$0.06
EPS Surpr.
-366.7%
Revenue
$0.01B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.20
EPS Surpr.
-15.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.15 | $-0.11 | $-0.04 | 2 |
| Q3 FY2027 | $-0.11 | $-0.08 | $-0.03 | 2 |
| Q2 FY2027 | $-0.59 | $-0.43 | $-0.15 | 2 |
| Q1 FY2027 | $-0.52 | $-0.38 | $-0.13 | 2 |
| Q4 FY2026 | $-0.33 | $-0.24 | $-0.08 | 4 |
| Q3 FY2026 | $-0.27 | $-0.23 | $-0.18 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.2B | 3 |
| Q3 FY2027 | $0.0B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +30.3% | $3.85 | $3.98 | +3.38% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -27.9% | $3.47 | $3.48 | +0.29% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +110.0% | $3.13 | $3.19 | +1.92% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -140.0% | $2.95 | $3.02 | +2.37% |
| ▲ Q2 FY2025 | May 12, 2025 | +5.3% | $1.58 | $1.51 | -4.43% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -366.7% | $1.30 | $1.29 | -0.77% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -15.0% | $1.80 | $1.76 | -2.22% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +15.2% | $2.04 | $2.07 | +1.47% |
Q2 FY2026+3.38%
Report Date
May 11, 2026
EPS Beat/Miss
+30.3%
Price Before
$3.85
Price After
$3.98
Q1 FY2026+0.29%
Report Date
Mar 19, 2026
EPS Beat/Miss
-27.9%
Price Before
$3.47
Price After
$3.48
Q4 FY2025+1.92%
Report Date
Nov 7, 2025
EPS Beat/Miss
+110.0%
Price Before
$3.13
Price After
$3.19
Q3 FY2025+2.37%
Report Date
Aug 4, 2025
EPS Beat/Miss
-140.0%
Price Before
$2.95
Price After
$3.02
Q2 FY2025-4.43%
Report Date
May 12, 2025
EPS Beat/Miss
+5.3%
Price Before
$1.58
Price After
$1.51
Q1 FY2025-0.77%
Report Date
Mar 13, 2025
EPS Beat/Miss
-366.7%
Price Before
$1.30
Price After
$1.29
Q4 FY2024-2.22%
Report Date
Nov 4, 2024
EPS Beat/Miss
-15.0%
Price Before
$1.80
Price After
$1.76
Q3 FY2024+1.47%
Report Date
Aug 6, 2024
EPS Beat/Miss
+15.2%
Price Before
$2.04
Price After
$2.07
Avg Beat Reaction+0.58%
Avg Miss Reaction-0.08%
Beat Rate4 / 8 quarters
Largest Move-4.43% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLLS ends December
Cellectis S.A. (CLLS) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.18 — beating the analyst consensus of $-0.26 by +30.3%. The next CLLS earnings date is expected around September 1, 2026.
Each quarter, investors track CLLS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLLS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLLS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLLS earnings · 5 questionsCellectis S.A.'s next earnings report is expected around September 1, 2026. CLLS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLLS historically reports after market close (AMC).
CLLS earnings datewhen is CLLS earningsCLLS next earnings datewhen does CLLS report earningsCLLS earnings calendar
▸ Source: FMP · Cellectis S.A. SEC filings · US GAAP · Cellectis S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026